Strategic Partnerships Lunit is actively forming collaborations with leading biology and pathology players such as 10x Genomics and Leica Indica Labs to develop AI-powered assays and integrate AI pathology with spatial molecular data, presenting opportunities to bundle radiology AI with downstream pathology workflows and molecular data integration.

Global Expansion Recent moves include expanding European presence with a relocation to Amsterdam and a rapidly growing installed base in 47 Dutch hospitals, signaling openness to venue-based sales plays, regional partnerships, and co-marketing in Europe.

Uptick in Adoption Lunit’s AI suite is deployed across thousands of sites globally with validated publications in top journals, indicating a mature product with proven clinical credibility, which strengthens value propositions around efficiency gains, diagnostic accuracy, and potential reimbursement discussions.

Clinical Research Tie‑ins Ongoing engagement with oncology and radiology research communities through WCLC presentations and oncology-focused AI tools points to sales angles around clinical trials, research collaborations, and data partnerships to accelerate adoption in new indications.

End-to-End AI Platform A diverse tech stack and multi-solution portfolio spanning chest X-ray, mammography, DBT, and triage, along with oncology AI initiatives, provides cross-sell opportunities to healthcare providers seeking integrated imaging workflows and unified AI governance across departments.